Fennec Pharma
FENC9.9102.69% ( +0.260 )
Fennec Pharma (FENC)
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company’s product candidate includes PEDMARK, a f...
- Open
- 9.710
- High
- 10.384
- Low
- 9.470
- Prev. Close
- 9.650
- Volume
- 90.55K
- Turnover
- 892.82K
- Avg Price
- 9.860
- Bid/Ask Ratio
- --
- Amplitude
- 9.47%
- 52wk High
- 11.310
- Volume Ratio
- 0.69
- Turnover Ratio
- 0.54%
Fennec Pharma Analyst Rating
View MoreForecast & Rating
Jun 10, 2026Price forecast
$15.6758.09%
Forecast & RatingStrong buy
6analysts
- Strong buy66.67%
- Buy33.33%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- Market Beat · Jul 10 at 03:29 AM
Adherex Technologies Inc. (NASDAQ:FENC) Receives Average Rating of "Moderate Buy" from Analysts
- PUBT · Jul 2 at 03:06 PM
Fennec Pharma former director Rosty Raykov disposes of 9,599 common shares for $99,926.59
- StockTitan · Jun 10 at 07:30 AM
Fennec Announces Results of Annual Meeting | FENC Stock News
- Market Beat · May 23 at 09:05 AM
Adherex Technologies’ PEDMARK Push Targets Larger AYA Market After Record Quarter
- StockTitan · May 21 at 09:01 AM
Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting | FENC Stock News
- StockTitan · May 18 at 07:30 AM
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | FENC Stock News
